MedTrace Logo

Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients

NCT04565379 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2022-01-28

No results posted yet for this study

Summary

A randomized, double blind, placebo-controlled, phase 2 clinical trial to investigate the efficacy and safety of 2 doses of NuSepin® intravenous infusion in COVID-19 pneumonia patients

Conditions

  • COVID19 Pneumonia

Interventions

DRUG

NuSepin® 0.1 mg

NuSepin® 0.1 mg

DRUG

NuSepin® 0.2 mg

NuSepin® 0.2 mg

DRUG

Placebo

Normal Saline

Sponsors & Collaborators

  • Shaperon

    lead INDUSTRY

Principal Investigators

  • Seung-Yong Seong, Dr. · Shaperon Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-24
Primary Completion
2021-04-13
Completion
2021-04-13

Countries

  • Romania

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04565379 on ClinicalTrials.gov